{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:49:56Z","timestamp":1794660596431,"version":"4.9.1"},"reference-count":238,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41584-025-01326-6","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T14:38:19Z","timestamp":1763995099000},"page":"151-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The obesity\u2013inflammation axis in psoriatic disease: mechanisms and therapeutic strategies"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7119-8136","authenticated-orcid":false,"given":"Rebecca H.","family":"Haberman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose U.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1715","authenticated-orcid":false,"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"1326_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong, A. W. et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 157, 940\u2013946 (2021).","journal-title":"JAMA Dermatol."},{"key":"1326_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin, C. T., Colbert, R. A. & Gladman, D. D. Psoriatic arthritis. N. Engl. J. Med. 376, 957\u2013970 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1326_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","volume":"18","author":"G Schett","year":"2022","unstructured":"Schett, G. et al. Psoriatic arthritis from a mechanistic perspective. Nat. Rev. Rheumatol. 18, 311\u2013325 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1326_CR4","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton, S. et al. Obesity in adults: a clinical practice guideline. CMAJ 192, E875\u2013E891 (2020).","journal-title":"CMAJ"},{"key":"1326_CR5","first-page":"51s","volume":"6","author":"[No authors listed]","year":"1998","unstructured":"[No authors listed] Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults \u2014 the evidence report. National Institutes of Health. Obes. Res. 6, 51s\u2013209s (1998).","journal-title":"Obes. Res."},{"key":"1326_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann, A. L. et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 55, 829\u2013835 (2006).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1326_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.annder.2015.06.024","volume":"143","author":"C Phan","year":"2016","unstructured":"Phan, C. et al. Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases. Ann. Dermatol. Venereol. 143, 264\u2013274 (2016).","journal-title":"Ann. Dermatol. Venereol."},{"key":"1326_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3899\/jrheum.160532","volume":"44","author":"L Eder","year":"2017","unstructured":"Eder, L., Abji, F., Rosen, C. F., Chandran, V. & Gladman, D. D. The association between obesity and clinical features of psoriatic arthritis: a case-control study. J. Rheumatol. 44, 437\u2013443 (2017).","journal-title":"J. Rheumatol."},{"key":"1326_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.22185","volume":"66","author":"M Labitigan","year":"2014","unstructured":"Labitigan, M. et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res. 66, 600\u2013607 (2014).","journal-title":"Arthritis Care Res."},{"key":"1326_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/annrheumdis-2023-eular.3678","volume":"82","author":"M Stirnimann","year":"2023","unstructured":"Stirnimann, M. et al. Obesity in psoriatic arthritis is increasingly affecting men and appears less dependent of socioeconomic status than in the general population [abstract OP0064]. Ann. Rheum. Dis. 82, 44 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/jid.2011.365","volume":"132","author":"SM Langan","year":"2012","unstructured":"Langan, S. M. et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J. Invest. Dermatol. 132, 556\u2013562 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"1326_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/acr.25230","volume":"76","author":"A Ishchenko","year":"2024","unstructured":"Ishchenko, A., Pazmino, S., Neerinckx, B., Lories, R. & de Vlam, K. Comorbidities in early psoriatic arthritis: data from the Metabolic Disturbances in Psoriatic Arthritis Cohort Study. Arthritis Care Res. 76, 231\u2013240 (2024).","journal-title":"Arthritis Care Res."},{"key":"1326_CR13","first-page":"1815","volume":"41","author":"S Scriffignano","year":"2023","unstructured":"Scriffignano, S. et al. Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populations. Clin. Exp. Rheumatol. 41, 1815\u20131822 (2023).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1326_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder, L., Thavaneswaran, A., Chandran, V., Cook, R. J. & Gladman, D. D. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann. Rheum. Dis. 74, 813\u2013817 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000433528","volume":"231","author":"A Jacobi","year":"2015","unstructured":"Jacobi, A., Langenbruch, A., Purwins, S., Augustin, M. & Radtke, M. A. Prevalence of obesity in patients with psoriasis: results of the national study PsoHealth3. Dermatology 231, 231\u2013238 (2015).","journal-title":"Dermatology"},{"key":"1326_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s13555-019-0314-1","volume":"9","author":"PEH Schwarz","year":"2019","unstructured":"Schwarz, P. E. H., Pinter, A., Melzer, N., Barteczek, P. & Reinhardt, M. ERAPSO: revealing the high burden of obesity in German psoriasis patients. Dermatol. Ther. 9, 579\u2013587 (2019).","journal-title":"Dermatol. Ther."},{"key":"1326_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong, A. W., Harskamp, C. T. & Armstrong, E. J. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr. Diabetes 2, e54 (2012).","journal-title":"Nutr. Diabetes"},{"key":"1326_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016400","volume":"98","author":"R Queiro","year":"2019","unstructured":"Queiro, R., Lorenzo, A., Tej\u00f3n, P., Coto, P. & Pardo, E. Obesity in psoriatic arthritis: comparative prevalence and associated factors. Medicine 98, e16400 (2019).","journal-title":"Medicine"},{"key":"1326_CR19","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1093\/rheumatology\/keaa720","volume":"60","author":"E Toussirot","year":"2020","unstructured":"Toussirot, E. et al. Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. Rheumatology 60, 2816\u20132825 (2020).","journal-title":"Rheumatology"},{"key":"1326_CR20","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1016\/j.jid.2017.07.822","volume":"137","author":"I Snekvik","year":"2017","unstructured":"Snekvik, I. et al. Obesity, Waist Circumference, weight change, and risk of incident psoriasis: prospective data from the HUNT study. J. Invest. Dermatol. 137, 2484\u20132490 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"1326_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/jdv.12001","volume":"27","author":"S Kumar","year":"2013","unstructured":"Kumar, S., Han, J., Li, T. & Qureshi, A. A. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J. Eur. Acad. Dermatol. Venereol. 27, 1293\u20131298 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/archinte.167.15.1670","volume":"167","author":"AR Setty","year":"2007","unstructured":"Setty, A. R., Curhan, G. & Choi, H. K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses\u2019 Health Study II. Arch. Intern. Med. 167, 1670\u20131675 (2007).","journal-title":"Arch. Intern. Med."},{"key":"1326_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2340\/00015555-2530","volume":"97","author":"K Danielsen","year":"2017","unstructured":"Danielsen, K., Wilsgaard, T., Olsen, A. O. & Furberg, A. S. Overweight and weight gain predict psoriasis development in a population-based cohort. Acta Derm. Venereol. 97, 332\u2013339 (2017).","journal-title":"Acta Derm. Venereol."},{"key":"1326_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.24121","volume":"73","author":"RS Thomsen","year":"2021","unstructured":"Thomsen, R. S. et al. Adiposity and physical activity as risk factors for developing psoriatic arthritis: longitudinal data from a population-based study in Norway. Arthritis Care Res. 73, 432\u2013441 (2021).","journal-title":"Arthritis Care Res."},{"key":"1326_CR25","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/annrheumdis-2011-201273","volume":"71","author":"W Li","year":"2012","unstructured":"Li, W., Han, J. & Qureshi, A. A. Obesity and risk of incident psoriatic arthritis in US women. Ann. Rheum. Dis. 71, 1267\u20131272 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jid.2016.11.032","volume":"137","author":"RT Lewinson","year":"2017","unstructured":"Lewinson, R. T. et al. Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-based study. J. Invest. Dermatol. 137, 828\u2013835 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"1326_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/annrheumdis-2012-201299","volume":"71","author":"TJ Love","year":"2012","unstructured":"Love, T. J. et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann. Rheum. Dis. 71, 1273\u20131277 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjd.18227","volume":"182","author":"A Green","year":"2020","unstructured":"Green, A. et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br. J. Dermatol. 182, 714\u2013720 (2020).","journal-title":"Br. J. Dermatol."},{"key":"1326_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/archdermatol.2010.141","volume":"146","author":"R Soltani-Arabshahi","year":"2010","unstructured":"Soltani-Arabshahi, R. et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch. Dermatol. 146, 721\u2013726 (2010).","journal-title":"Arch. Dermatol."},{"key":"1326_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1365-2230.2008.02791.x","volume":"34","author":"ML Murray","year":"2009","unstructured":"Murray, M. L., Bergstresser, P. R., Adams-Huet, B. & Cohen, J. B. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin. Exp. Dermatol. 34, 140\u2013144 (2009).","journal-title":"Clin. Exp. Dermatol."},{"key":"1326_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-4632.2011.05270.x","volume":"52","author":"GV Duarte","year":"2013","unstructured":"Duarte, G. V. et al. Association between obesity measured by different parameters and severity of psoriasis. Int. J. Dermatol. 52, 177\u2013181 (2013).","journal-title":"Int. J. Dermatol."},{"key":"1326_CR32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1468-3083.2010.03573.x","volume":"24","author":"YH Huang","year":"2010","unstructured":"Huang, Y. H. et al. Relationships between obesity and the clinical severity of psoriasis in Taiwan. J. Eur. Acad. Dermatol. Venereol. 24, 1035\u20131039 (2010).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-94505-0","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. BMI matters: understanding the link between weight and severe psoriasis. Sci. Rep. 15, 11158 (2025).","journal-title":"Sci. Rep."},{"key":"1326_CR34","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3899\/jrheum.130949","volume":"41","author":"L Eder","year":"2014","unstructured":"Eder, L. et al. Is the MAdrid Sonographic Enthesitis Index useful for differentiating psoriatic arthritis from psoriasis alone and healthy controls? J. Rheumatol. 41, 466\u2013472 (2014).","journal-title":"J. Rheumatol."},{"key":"1326_CR35","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10067-012-1999-z","volume":"31","author":"KJ Kim","year":"2012","unstructured":"Kim, K. J. et al. Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis. Clin. Rheumatol. 31, 1231\u20131238 (2012).","journal-title":"Clin. Rheumatol."},{"key":"1326_CR36","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/14397595.2016.1265637","volume":"27","author":"SK Kim","year":"2017","unstructured":"Kim, S. K., Choe, J. Y., Lee, S. S. & Shin, K. Body mass index is related with the presence of syndesmophyte in axial spondyloarthritis: data from the Korean College of Rheumatology BIOlogics (KOBIO) registry. Mod. Rheumatol. 27, 855\u2013861 (2017).","journal-title":"Mod. Rheumatol."},{"key":"1326_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122693","volume":"10","author":"F Maas","year":"2015","unstructured":"Maas, F. et al. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-\u03b1 blocking therapy: a prospective longitudinal observational cohort study. PLoS ONE 10, e0122693 (2015).","journal-title":"PLoS ONE"},{"key":"1326_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00296-015-3360-8","volume":"36","author":"SZ Aydin","year":"2016","unstructured":"Aydin, S. Z. et al. A relationship between spinal new bone formation in ankylosing spondylitis and the sonographically determined Achilles tendon enthesophytes. Rheumatol. Int. 36, 397\u2013404 (2016).","journal-title":"Rheumatol. Int."},{"key":"1326_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003157","volume":"9","author":"YY Leung","year":"2023","unstructured":"Leung, Y. Y. et al. Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study. RMD Open 9, e003157 (2023).","journal-title":"RMD Open"},{"key":"1326_CR40","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3899\/jrheum.190219","volume":"47","author":"JA Walsh","year":"2020","unstructured":"Walsh, J. A. et al. Measuring outcomes in psoriatic arthritis: comparing routine assessment of patient index data and psoriatic arthritis impact of disease. J. Rheumatol. 47, 1496\u20131505 (2020).","journal-title":"J. Rheumatol."},{"key":"1326_CR41","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro, F. et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin. Drug. Investig. 41, 917\u2013925 (2021).","journal-title":"Clin. Drug. Investig."},{"key":"1326_CR42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/jdv.13771","volume":"31","author":"A Chiricozzi","year":"2017","unstructured":"Chiricozzi, A. et al. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. J. Eur. Acad. Dermatol. Venereol. 31, 304\u2013311 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR43","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1111\/jocd.15217","volume":"21","author":"N Demirel \u00d6\u011f\u00fct","year":"2022","unstructured":"Demirel \u00d6\u011f\u00fct, N., Ko\u00e7 Y\u0131ld\u0131r\u0131m, S., Erba\u011fc\u0131, E. & Hapa, F. A. Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting. J. Cosmet. Dermatol. 21, 6215\u20136224 (2022).","journal-title":"J. Cosmet. Dermatol."},{"key":"1326_CR44","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/jdv.16202","volume":"34","author":"N Rompoti","year":"2020","unstructured":"Rompoti, N. et al. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J. Eur. Acad. Dermatol. Venereol. 34, 1240\u20131247 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000156599","volume":"217","author":"L Naldi","year":"2008","unstructured":"Naldi, L. et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 217, 365\u2013373 (2008).","journal-title":"Dermatology"},{"key":"1326_CR46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2021.06.883","volume":"86","author":"CW Enos","year":"2022","unstructured":"Enos, C. W. et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry. J. Am. Acad. Dermatol. 86, 68\u201376 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1326_CR47","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s13555-021-00556-2","volume":"11","author":"S Gkalpakiotis","year":"2021","unstructured":"Gkalpakiotis, S. et al. Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from the Czech Republic. Dermatol. Ther. 11, 1345\u20131355 (2021).","journal-title":"Dermatol. Ther."},{"key":"1326_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.18594","volume":"37","author":"A Narcisi","year":"2023","unstructured":"Narcisi, A. et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J. Eur. Acad. Dermatol. Venereol. 37, 93\u2013103 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR49","volume":"35","author":"G Caldarola","year":"2022","unstructured":"Caldarola, G. et al. Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1 year real-life study. Dermatol. Ther. 35, e15489 (2022).","journal-title":"Dermatol. Ther."},{"key":"1326_CR50","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3846","volume":"101","author":"G Malara","year":"2021","unstructured":"Malara, G. et al. Effectiveness of apremilast in real life in patients with psoriasis: a longitudinal study. Acta Derm. Venereol. 101, adv00545 (2021).","journal-title":"Acta Derm. Venereol."},{"key":"1326_CR51","doi-asserted-by":"publisher","first-page":"AB158","DOI":"10.1016\/j.jaad.2023.07.635","volume":"89","author":"RG Langley","year":"2023","unstructured":"Langley, R. G. et al. Efficacy of apremilast in patients with moderate-to-severe plaque psoriasis across weight and BMI subgroups: analysis from ESTEEM 1 and ESTEEM 2 [abstract 43250]. J. Am. Acad. Dermatol. 89, AB158 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1326_CR52","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamadermatol.2025.0288","volume":"161","author":"HJ Kim","year":"2025","unstructured":"Kim, H. J., Lee, E. H. & Jung, Y. Association of obesity and innate immune markers with resistance to biologic therapy in psoriasis. JAMA Dermatol. 161, 629\u2013634 (2025).","journal-title":"JAMA Dermatol."},{"key":"1326_CR53","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000513398","volume":"237","author":"F Assan","year":"2021","unstructured":"Assan, F. et al. First-Line biologic therapy and obesity in moderate-to-severe psoriasis: results from the prospective multicenter cohort Psobioteq. Dermatology 237, 338\u2013346 (2021).","journal-title":"Dermatology"},{"key":"1326_CR54","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","volume":"135","author":"RB Warren","year":"2015","unstructured":"Warren, R. B. et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J. Invest. Dermatol. 135, 2632\u20132640 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"1326_CR55","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","volume":"181","author":"A Mourad","year":"2019","unstructured":"Mourad, A., Straube, S., Armijo-Olivo, S. & Gniadecki, R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br. J. Dermatol. 181, 450\u2013458 (2019).","journal-title":"Br. J. Dermatol."},{"key":"1326_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/acr.21711","volume":"65","author":"MN di Minno","year":"2013","unstructured":"di Minno, M. N. et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res. 65, 141\u2013147 (2013).","journal-title":"Arthritis Care Res."},{"key":"1326_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061474","volume":"12","author":"E Vallejo-Yag\u00fce","year":"2022","unstructured":"Vallejo-Yag\u00fce, E., Burkard, T., Micheroli, R. & Burden, A. M. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open 12, e061474 (2022).","journal-title":"BMJ Open"},{"key":"1326_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh, S. et al. Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE 13, e0195123 (2018).","journal-title":"PLoS ONE"},{"key":"1326_CR59","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","volume":"55","author":"P H\u00f8jgaard","year":"2016","unstructured":"H\u00f8jgaard, P. et al. The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology 55, 2191\u20132199 (2016).","journal-title":"Rheumatology"},{"key":"1326_CR60","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3899\/jrheum.171034","volume":"46","author":"A Ogdie","year":"2019","unstructured":"Ogdie, A. et al. Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor. J. Rheumatol. 46, 475\u2013482 (2019).","journal-title":"J. Rheumatol."},{"key":"1326_CR61","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10067-018-4004-7","volume":"37","author":"R Queiro","year":"2018","unstructured":"Queiro, R. & Ca\u00f1ete, J. D. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association? Clin. Rheumatol. 37, 661\u2013666 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1326_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp, K. et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J. Am. Acad. Dermatol. 73, 37\u201349 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1326_CR63","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","volume":"51","author":"ZS Yang","year":"2016","unstructured":"Yang, Z. S., Lin, N. N., Li, L. & Li, Y. The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin. Rev. Allergy Immunol. 51, 240\u2013247 (2016).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1326_CR64","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1468-3083.2007.02429.x","volume":"22","author":"P Gisondi","year":"2008","unstructured":"Gisondi, P., Cotena, C., Tessari, G. & Girolomoni, G. Anti-tumour necrosis factor-\u03b1 therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J. Eur. Acad. Dermatol. Venereol. 22, 341\u2013344 (2008).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00481","volume":"11","author":"O Patsalos","year":"2020","unstructured":"Patsalos, O., Dalton, B., Leppanen, J., Ibrahim, M. A. A. & Himmerich, H. Impact of TNF-\u03b1 inhibitors on body weight and BMI: a systematic review and meta-analysis. Front. Pharmacol. 11, 481 (2020).","journal-title":"Front. Pharmacol."},{"key":"1326_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03518-7","volume":"27","author":"RH Haberman","year":"2025","unstructured":"Haberman, R. H. et al. Burden and determinants of multi-b\/tsDMARD failure in psoriatic arthritis. Arthritis Res. Ther. 27, 46 (2025).","journal-title":"Arthritis Res. Ther."},{"key":"1326_CR67","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","volume":"57","author":"C Stober","year":"2018","unstructured":"Stober, C. et al. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology 57, 158\u2013163 (2018).","journal-title":"Rheumatology"},{"key":"1326_CR68","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/acr.25112","volume":"75","author":"MA Rida","year":"2023","unstructured":"Rida, M. A., Lee, K. A., Chandran, V., Cook, R. J. & Gladman, D. D. Persistence of biologics in the treatment of psoriatic arthritis: data from a large hospital-based longitudinal cohort. Arthritis Care Res. 75, 2174\u20132181 (2023).","journal-title":"Arthritis Care Res."},{"key":"1326_CR69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40259-022-00522-0","volume":"36","author":"M Bassi","year":"2022","unstructured":"Bassi, M. & Singh, S. Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases. BioDrugs 36, 197\u2013203 (2022).","journal-title":"BioDrugs"},{"key":"1326_CR70","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jaad.2009.11.012","volume":"63","author":"M Lebwohl","year":"2010","unstructured":"Lebwohl, M. et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J. Am. Acad. Dermatol. 63, 571\u2013579 (2010).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1326_CR71","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s13555-025-01394-2","volume":"15","author":"E Mortato","year":"2025","unstructured":"Mortato, E. et al. Predictive factors for super responder status and long-term effectiveness of guselkumab in psoriasis: a multicenter retrospective study. Dermatol. Ther. 15, 1239\u20131250 (2025).","journal-title":"Dermatol. Ther."},{"key":"1326_CR72","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","volume":"25","author":"L Puig","year":"2011","unstructured":"Puig, L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J. Eur. Acad. Dermatol. Venereol. 25, 1007\u20131011 (2011).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR73","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cpt.1478","volume":"106","author":"JE Lee","year":"2019","unstructured":"Lee, J. E. et al. Effect of body weight on risk-benefit and dosing regimen recommendation of secukinumab for the treatment of moderate to severe plaque psoriasis. Clin. Pharmacol. Ther. 106, 78\u201380 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1326_CR74","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MN Di Minno","year":"2014","unstructured":"Di Minno, M. N. et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers. Ann. Rheum. Dis. 73, 1157\u20131162 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR75","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer, R. J., Huitema, A. D., Schellens, J. H. & Beijnen, J. H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 493\u2013507 (2010).","journal-title":"Clin. Pharmacokinet."},{"key":"1326_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678355","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang, S. et al. The alterations in and the role of the Th17\/Treg balance in metabolic diseases. Front. Immunol. 12, 678355 (2021).","journal-title":"Front. Immunol."},{"key":"1326_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115082","volume":"161","author":"C Liu","year":"2025","unstructured":"Liu, C. & Li, X. Role of leptin and adiponectin in immune response and inflammation. Int. Immunopharmacol. 161, 115082 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"1326_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf9382","volume":"15","author":"MW Schleh","year":"2023","unstructured":"Schleh, M. W. et al. Metaflammation in obesity and its therapeutic targeting. Sci. Transl. Med. 15, eadf9382 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1326_CR79","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","volume":"542","author":"GS Hotamisligil","year":"2017","unstructured":"Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders. Nature 542, 177\u2013185 (2017).","journal-title":"Nature"},{"key":"1326_CR80","doi-asserted-by":"publisher","first-page":"E797","DOI":"10.1503\/cmaj.250502","volume":"197","author":"SD Pedersen","year":"2025","unstructured":"Pedersen, S. D. et al. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ 197, E797\u2013E809 (2025).","journal-title":"CMAJ"},{"key":"1326_CR81","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","volume":"15","author":"M Bluher","year":"2019","unstructured":"Bluher, M. Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 15, 288\u2013298 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1326_CR82","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nrendo.2013.57","volume":"9","author":"JS El-Sayed Moustafa","year":"2013","unstructured":"El-Sayed Moustafa, J. S. & Froguel, P. From obesity genetics to the future of personalized obesity therapy. Nat. Rev. Endocrinol. 9, 402\u2013413 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1326_CR83","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41580-023-00680-1","volume":"25","author":"CE Hagberg","year":"2024","unstructured":"Hagberg, C. E. & Spalding, K. L. White adipocyte dysfunction and obesity-associated pathologies in humans. Nat. Rev. Mol. Cell Biol. 25, 270\u2013289 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1326_CR84","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cmet.2017.12.002","volume":"27","author":"RK Zwick","year":"2018","unstructured":"Zwick, R. K., Guerrero-Juarez, C. F., Horsley, V. & Plikus, M. V. Anatomical, physiological, and functional diversity of adipose tissue. Cell Metab. 27, 68\u201383 (2018).","journal-title":"Cell Metab."},{"key":"1326_CR85","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41366-024-01668-3","volume":"49","author":"J Gomez-Ambrosi","year":"2025","unstructured":"Gomez-Ambrosi, J., Catalan, V. & Fruhbeck, G. The evolution of the understanding of obesity over the last 100 years. Int. J. Obes. 49, 168\u2013176 (2025).","journal-title":"Int. J. Obes."},{"key":"1326_CR86","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.celrep.2015.07.014","volume":"12","author":"Y Endo","year":"2015","unstructured":"Endo, Y. et al. Obesity drives Th17 cell differentiation by inducing the lipid metabolic kinase, ACC1. Cell Rep. 12, 1042\u20131055 (2015).","journal-title":"Cell Rep."},{"key":"1326_CR87","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/oby.23528","volume":"30","author":"GH Pugh","year":"2022","unstructured":"Pugh, G. H. et al. T cells dominate peripheral inflammation in a cross-sectional analysis of obesity-associated diabetes. Obesity 30, 1983\u20131994 (2022).","journal-title":"Obesity"},{"key":"1326_CR88","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1172\/JCI200319246","volume":"112","author":"SP Weisberg","year":"2003","unstructured":"Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796\u20131808 (2003).","journal-title":"J. Clin. Invest."},{"key":"1326_CR89","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41423-021-00791-9","volume":"19","author":"SK Wculek","year":"2022","unstructured":"Wculek, S. K., Dunphy, G., Heras-Murillo, I., Mastrangelo, A. & Sancho, D. Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol. Immunol. 19, 384\u2013408 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"1326_CR90","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41574-023-00932-2","volume":"20","author":"SR Shaikh","year":"2024","unstructured":"Shaikh, S. R., Beck, M. A., Alwarawrah, Y. & MacIver, N. J. Emerging mechanisms of obesity-associated immune dysfunction. Nat. Rev. Endocrinol. 20, 136\u2013148 (2024).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1326_CR91","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s42255-021-00371-1","volume":"3","author":"A Teijeiro","year":"2021","unstructured":"Teijeiro, A., Garrido, A., Ferre, A., Perna, C. & Djouder, N. Inhibition of the IL-17A axis in adipocytes suppresses diet-induced obesity and metabolic disorders in mice. Nat. Metab. 3, 496\u2013512 (2021).","journal-title":"Nat. Metab."},{"key":"1326_CR92","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41577-024-01103-8","volume":"25","author":"H Tilg","year":"2025","unstructured":"Tilg, H., Ianiro, G., Gasbarrini, A. & Adolph, T. E. Adipokines: masterminds of metabolic inflammation. Nat. Rev. Immunol. 25, 250\u2013265 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1326_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622468","volume":"11","author":"K Kiernan","year":"2020","unstructured":"Kiernan, K. & MacIver, N. J. The role of the adipokine leptin in immune cell function in health and disease. Front. Immunol. 11, 622468 (2020).","journal-title":"Front. Immunol."},{"key":"1326_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-025-02565-5","author":"M Fatica","year":"2025","unstructured":"Fatica, M. et al. Metabolic challenges of glucose and lipid dysregulation in psoriatic arthritis: a narrative review from pathogenesis to clinical practice. Acta Diabetol. https:\/\/doi.org\/10.1007\/s00592-025-02565-5 (2025).","journal-title":"Acta Diabetol."},{"key":"1326_CR95","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/rheumatology\/keaa604","volume":"60","author":"LD Ferguson","year":"2021","unstructured":"Ferguson, L. D. et al. Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity \u2014 a cross-sectional study. Rheumatology 60, 1858\u20131862 (2021).","journal-title":"Rheumatology"},{"key":"1326_CR96","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/sj.ijo.0801723","volume":"25","author":"NG Forouhi","year":"2001","unstructured":"Forouhi, N. G., Sattar, N. & McKeigue, P. M. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int. J. Obes. Relat. Metab. Disord. 25, 1327\u20131331 (2001).","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"1326_CR97","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.diabres.2004.11.007","volume":"69","author":"HS Park","year":"2005","unstructured":"Park, H. S., Park, J. Y. & Yu, R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-\u03b1 and IL-6. Diabetes Res. Clin. Pract. 69, 29\u201335 (2005).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1326_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002321","volume":"8","author":"SS Zhao","year":"2022","unstructured":"Zhao, S. S., Bowes, J., Barton, A., Davey Smith, G. & Richardson, T. Separating the effects of childhood and adult body size on inflammatory arthritis: a Mendelian randomisation study. RMD Open 8, e002321 (2022).","journal-title":"RMD Open"},{"key":"1326_CR99","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamadermatol.2022.6051","volume":"159","author":"SS Zhao","year":"2023","unstructured":"Zhao, S. S., Yiu, Z. Z. N., Barton, A. & Bowes, J. Association of lipid-lowering drugs with risk of psoriasis: a Mendelian randomization study. JAMA Dermatol. 159, 275\u2013280 (2023).","journal-title":"JAMA Dermatol."},{"key":"1326_CR100","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/annrheumdis-2022-eular.408","volume":"81","author":"SS Zhao","year":"2022","unstructured":"Zhao, S. S. & Bowes, B. A. J. Impaired glycaemic control is associated with increased risk of psoriatic arthritis: Mendelian randomisation study [abstract POS0307]. Ann. Rheum Dis. 81, 403 (2022).","journal-title":"Ann. Rheum Dis."},{"key":"1326_CR101","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jid.2022.11.014","volume":"143","author":"JQ Jin","year":"2023","unstructured":"Jin, J. Q. et al. Mendelian Randomization studies in psoriasis and psoriatic arthritis: a systematic review. J. Invest. Dermatol. 143, 762\u2013776.e3 (2023).","journal-title":"J. Invest. Dermatol."},{"key":"1326_CR102","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","volume":"20","author":"WH Boehncke","year":"2011","unstructured":"Boehncke, W. H., Boehncke, S., Tobin, A. M. & Kirby, B. The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp. Dermatol. 20, 303\u2013307 (2011).","journal-title":"Exp. Dermatol."},{"key":"1326_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14292-1","volume":"7","author":"S Nakamizo","year":"2017","unstructured":"Nakamizo, S. et al. High fat diet exacerbates murine psoriatic dermatitis by increasing the number of IL-17-producing \u03b3\u03b4 T cells. Sci. Rep. 7, 14076 (2017).","journal-title":"Sci. Rep."},{"key":"1326_CR104","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/exd.13484","volume":"27","author":"Y Higashi","year":"2018","unstructured":"Higashi, Y. et al. High-fat diet exacerbates imiquimod-induced psoriasis-like dermatitis in mice. Exp. Dermatol. 27, 178\u2013184 (2018).","journal-title":"Exp. Dermatol."},{"key":"1326_CR105","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.immuni.2015.04.016","volume":"42","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. et al. Epidermal fatty acid binding protein promotes skin inflammation induced by high-fat diet. Immunity 42, 953\u2013964 (2015).","journal-title":"Immunity"},{"key":"1326_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.606560","volume":"11","author":"E Toussirot","year":"2020","unstructured":"Toussirot, E. Mini-Review: the contribution of adipokines to joint inflammation in inflammatory rheumatic diseases. Front. Endocrinol. 11, 606560 (2020).","journal-title":"Front. Endocrinol."},{"key":"1326_CR107","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1136\/annrheumdis-2012-202325","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder, L. et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann. Rheum. Dis. 72, 1956\u20131961 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15030206","volume":"15","author":"M Radic","year":"2025","unstructured":"Radic, M. et al. Cardiometabolic risk in psoriatic arthritis: a hidden burden of inflammation and metabolic dysregulation. Metabolites 15, 206 (2025).","journal-title":"Metabolites"},{"key":"1326_CR109","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000481882","volume":"233","author":"A Kyriakou","year":"2017","unstructured":"Kyriakou, A., Patsatsi, A., Sotiriadis, D. & Goulis, D. G. Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology 233, 378\u2013389 (2017).","journal-title":"Dermatology"},{"key":"1326_CR110","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1365-2133.2008.08742.x","volume":"159","author":"AA Cerman","year":"2008","unstructured":"Cerman, A. A. et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br. J. Dermatol. 159, 820\u2013826 (2008).","journal-title":"Br. J. Dermatol."},{"key":"1326_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13102959","volume":"13","author":"E Toledano","year":"2024","unstructured":"Toledano, E. et al. Clinical features and disease activity in psoriatic arthritis: a sex-related perspective on leptin and comorbidity. J. Clin. Med. 13, 2959 (2024).","journal-title":"J. Clin. Med."},{"key":"1326_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046740","volume":"7","author":"Y Xue","year":"2012","unstructured":"Xue, Y. et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS ONE 7, e46740 (2012).","journal-title":"PLoS ONE"},{"key":"1326_CR113","doi-asserted-by":"publisher","first-page":"875","DOI":"10.4049\/jimmunol.168.2.875","volume":"168","author":"N Busso","year":"2002","unstructured":"Busso, N. et al. Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J. Immunol. 168, 875\u2013882 (2002).","journal-title":"J. Immunol."},{"key":"1326_CR114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021096118","volume":"118","author":"K Collins","year":"2021","unstructured":"Collins, K. et al. Adipose tissue is a critical regulator of osteoarthritis. Proc. Natl Acad. Sci. USA 118, e2021096118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1326_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590749","volume":"11","author":"S Porta","year":"2020","unstructured":"Porta, S. et al. Adipokines, cardiovascular risk, and therapeutic management in obesity and psoriatic arthritis. Front. Immunol. 11, 590749 (2020).","journal-title":"Front. Immunol."},{"key":"1326_CR116","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1136\/annrheumdis-2016-210478","volume":"76","author":"F Eymard","year":"2017","unstructured":"Eymard, F. et al. Knee and hip intra-articular adipose tissues (IAATs) compared with autologous subcutaneous adipose tissue: a specific phenotype for a central player in osteoarthritis. Ann. Rheum. Dis. 76, 1142\u20131148 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR117","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.14336\/AD.2019.1116","volume":"11","author":"N Zeng","year":"2020","unstructured":"Zeng, N., Yan, Z. P., Chen, X. Y. & Ni, G. X. Infrapatellar fat pad and knee osteoarthritis. Aging Dis. 11, 1317\u20131328 (2020).","journal-title":"Aging Dis."},{"key":"1326_CR118","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/rheumatology\/keaa039","volume":"59","author":"EG Araujo","year":"2020","unstructured":"Araujo, E. G. & Schett, G. Enthesitis in psoriatic arthritis (part 1): pathophysiology. Rheumatology 59, i10\u2013i14 (2020).","journal-title":"Rheumatology"},{"key":"1326_CR119","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/annrheumdis-2016-209334","volume":"76","author":"SM Thorarensen","year":"2017","unstructured":"Thorarensen, S. M. et al. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann. Rheum. Dis. 76, 521\u2013525 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR120","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/acr.20496","volume":"63","author":"L Eder","year":"2011","unstructured":"Eder, L. et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res. 63, 1091\u20131097 (2011).","journal-title":"Arthritis Care Res."},{"key":"1326_CR121","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10067-013-2436-7","volume":"33","author":"J Hsieh","year":"2014","unstructured":"Hsieh, J., Kadavath, S. & Efthimiou, P. Can traumatic injury trigger psoriatic arthritis? A review of the literature. Clin. Rheumatol. 33, 601\u2013608 (2014).","journal-title":"Clin. Rheumatol."},{"key":"1326_CR122","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41584-019-0364-x","volume":"16","author":"E Gracey","year":"2020","unstructured":"Gracey, E. et al. Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis. Nat. Rev. Rheumatol. 16, 193\u2013207 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1326_CR123","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S2665-9913(23)00074-7","volume":"5","author":"LAN Crowe","year":"2023","unstructured":"Crowe, L. A. N. et al. Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine? Lancet Rheumatol. 5, e293\u2013e304 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1326_CR124","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3899\/jrheum.190540","volume":"47","author":"S Bakirci","year":"2020","unstructured":"Bakirci, S. et al. Entheseal changes in response to age, body mass index, and physical activity: an ultrasound study in healthy people. J. Rheumatol. 47, 968\u2013972 (2020).","journal-title":"J. Rheumatol."},{"key":"1326_CR125","doi-asserted-by":"publisher","first-page":"435","DOI":"10.55563\/clinexprheumatol\/zm9e6u","volume":"39","author":"P Falsetti","year":"2021","unstructured":"Falsetti, P., Conticini, E., Baldi, C., Acciai, C. & Frediani, B. High prevalence of ultrasound-defined enthesitis in patients with metabolic syndrome. Comment on: How normal is the enthesis by ultrasound in healthy subjects? Di Matteo et al. Clin. Exp. Rheumatol. 39, 435\u2013436 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1326_CR126","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1177\/03635465211049219","volume":"49","author":"SM Bolam","year":"2021","unstructured":"Bolam, S. M. et al. Obesity impairs enthesis healing after rotator cuff repair in a rat model. Am. J. Sports Med. 49, 3959\u20133969 (2021).","journal-title":"Am. J. Sports Med."},{"key":"1326_CR127","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","volume":"73","author":"P Jacques","year":"2014","unstructured":"Jacques, P. et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann. Rheum. Dis. 73, 437\u2013445 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR128","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/art.38892","volume":"67","author":"JU Scher","year":"2015","unstructured":"Scher, J. U. et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 67, 128\u2013139 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1326_CR129","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41575-023-00867-z","volume":"21","author":"PD Cani","year":"2024","unstructured":"Cani, P. D. & Van Hul, M. Gut microbiota in overweight and obesity: crosstalk with adipose tissue. Nat. Rev. Gastroenterol. Hepatol. 21, 164\u2013183 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1326_CR130","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1073\/pnas.0605374104","volume":"104","author":"F Backhed","year":"2007","unstructured":"Backhed, F., Manchester, J. K., Semenkovich, C. F. & Gordon, J. I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. USA 104, 979\u2013984 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1326_CR131","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","volume":"180","author":"JD Taurog","year":"1994","unstructured":"Taurog, J. D. et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med. 180, 2359\u20132364 (1994).","journal-title":"J. Exp. Med."},{"key":"1326_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101494","volume":"33","author":"B Myers","year":"2019","unstructured":"Myers, B. et al. The gut microbiome in psoriasis and psoriatic arthritis. Best. Pract. Res. Clin. Rheumatol. 33, 101494 (2019).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1326_CR133","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/ard-2024-225735","volume":"84","author":"JU Scher","year":"2025","unstructured":"Scher, J. U., Nayak, R. & Clemente, J. C. Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs. Ann. Rheum. Dis. 84, 9\u201313 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR134","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1073\/pnas.1219451110","volume":"110","author":"A Everard","year":"2013","unstructured":"Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl Acad. Sci. USA 110, 9066\u20139071 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1326_CR135","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9474896","volume":"2017","author":"X Guo","year":"2017","unstructured":"Guo, X. et al. High fat diet alters gut microbiota and the expression of Paneth cell-antimicrobial peptides preceding changes of circulating inflammatory cytokines. Mediators Inflamm. 2017, 9474896 (2017).","journal-title":"Mediators Inflamm."},{"key":"1326_CR136","doi-asserted-by":"publisher","first-page":"G518","DOI":"10.1152\/ajpgi.00024.2006","volume":"292","author":"P Brun","year":"2007","unstructured":"Brun, P. et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G518\u2013G525 (2007).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1326_CR137","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/JOE-20-0473","volume":"248","author":"M Regnier","year":"2021","unstructured":"Regnier, M., Van Hul, M., Knauf, C. & Cani, P. D. Gut microbiome, endocrine control of gut barrier function and metabolic diseases. J. Endocrinol. 248, R67\u2013R82 (2021).","journal-title":"J. Endocrinol."},{"key":"1326_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/nu17081323","volume":"17","author":"MG Bonomo","year":"2025","unstructured":"Bonomo, M. G., D\u2019Angelo, S., Picerno, V., Carriero, A. & Salzano, G. Recent advances in gut microbiota in psoriatic arthritis. Nutrients 17, 1323 (2025).","journal-title":"Nutrients"},{"key":"1326_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147499","volume":"23","author":"G Barros","year":"2022","unstructured":"Barros, G., Duran, P., Vera, I. & Bermudez, V. Exploring the links between obesity and psoriasis: a comprehensive review. Int. J. Mol. Sci. 23, 7499 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1326_CR140","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","volume":"71","author":"WM de Vos","year":"2022","unstructured":"de Vos, W. M., Tilg, H., Van Hul, M. & Cani, P. D. Gut microbiome and health: mechanistic insights. Gut 71, 1020\u20131032 (2022).","journal-title":"Gut"},{"key":"1326_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/nu14142970","volume":"14","author":"MC Buhas","year":"2022","unstructured":"Buhas, M. C. et al. Gut microbiota in psoriasis. Nutrients 14, 2970 (2022).","journal-title":"Nutrients"},{"key":"1326_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.853566","volume":"13","author":"Y Hao","year":"2022","unstructured":"Hao, Y. et al. Gut microbiota dysbiosis and altered bile acid catabolism lead to metabolic disorder in psoriasis mice. Front. Microbiol. 13, 853566 (2022).","journal-title":"Front. Microbiol."},{"key":"1326_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101493","volume":"35","author":"R Li","year":"2021","unstructured":"Li, R., Andreu-Sanchez, S., Kuipers, F. & Fu, J. Gut microbiome and bile acids in obesity-related diseases. Best. Pract. Res. Clin. Endocrinol. Metab. 35, 101493 (2021).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"1326_CR144","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/art.42288","volume":"75","author":"A Paine","year":"2023","unstructured":"Paine, A. et al. Dysregulation of bile acids, lipids, and nucleotides in psoriatic arthritis revealed by unbiased profiling of serum metabolites. Arthritis Rheumatol. 75, 53\u201363 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1326_CR145","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.759","volume":"10","author":"B Torres","year":"2024","unstructured":"Torres, B. et al. Use of probiotics in preventing and treating excess weight and obesity. A systematic review. Obes. Sci. Pract. 10, e759 (2024).","journal-title":"Obes. Sci. Pract."},{"key":"1326_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/life13071488","volume":"13","author":"D Hu","year":"2023","unstructured":"Hu, D., Zhao, J., Zhang, H., Wang, G. & Gu, Z. Fecal microbiota transplantation for weight and glycemic control of obesity as well as the associated metabolic diseases: meta-analysis and comprehensive assessment. Life 13, 1488 (2023).","journal-title":"Life"},{"key":"1326_CR147","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1136\/annrheumdis-2020-219511","volume":"80","author":"MS Kragsnaes","year":"2021","unstructured":"Kragsnaes, M. S. et al. Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. Ann. Rheum. Dis. 80, 1158\u20131167 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/nu14020354","volume":"14","author":"P Sanchez","year":"2022","unstructured":"Sanchez, P. et al. Efficacy of probiotics in rheumatoid arthritis and spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials. Nutrients 14, 354 (2022).","journal-title":"Nutrients"},{"key":"1326_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1340465","volume":"15","author":"MM Garcia","year":"2024","unstructured":"Garcia, M. M. et al. Adults with excess weight or obesity, but not with overweight, report greater pain intensities than individuals with normal weight: a systematic review and meta-analysis. Front. Endocrinol. 15, 1340465 (2024).","journal-title":"Front. Endocrinol."},{"key":"1326_CR150","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40744-025-00758-6","volume":"12","author":"D Currado","year":"2025","unstructured":"Currado, D. et al. The relationship between metabolic syndrome and pain catastrophizing in psoriatic arthritis. Rheumatol. Ther. 12, 581\u2013592 (2025).","journal-title":"Rheumatol. Ther."},{"key":"1326_CR151","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41584-024-01143-3","volume":"20","author":"M Binvignat","year":"2024","unstructured":"Binvignat, M., Sellam, J., Berenbaum, F. & Felson, D. T. The role of obesity and adipose tissue dysfunction in osteoarthritis pain. Nat. Rev. Rheumatol. 20, 565\u2013584 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1326_CR152","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00264-013-1982-6","volume":"37","author":"A Lubbeke","year":"2013","unstructured":"Lubbeke, A. et al. Do synovial leptin levels correlate with pain in end stage arthritis? Int. Orthop. 37, 2071\u20132079 (2013).","journal-title":"Int. Orthop."},{"key":"1326_CR153","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ando.2024.05.012","volume":"85","author":"N Zapata-Linares","year":"2024","unstructured":"Zapata-Linares, N., Berenbaum, F. & Houard, X. Role of joint adipose tissues in osteoarthritis. Ann. Endocrinol. 85, 214\u2013219 (2024).","journal-title":"Ann. Endocrinol."},{"key":"1326_CR154","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.joca.2014.04.018","volume":"22","author":"C Ballegaard","year":"2014","unstructured":"Ballegaard, C. et al. Knee pain and inflammation in the infrapatellar fat pad estimated by conventional and dynamic contrast-enhanced magnetic resonance imaging in obese patients with osteoarthritis: a cross-sectional study. Osteoarthr. Cartil. 22, 933\u2013940 (2014).","journal-title":"Osteoarthr. Cartil."},{"key":"1326_CR155","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MED.0b013e328321306c","volume":"16","author":"I Karagiannides","year":"2009","unstructured":"Karagiannides, I. & Pothoulakis, C. Substance P, obesity, and gut inflammation. Curr. Opin. Endocrinol. Diabetes Obes. 16, 47\u201352 (2009).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"1326_CR156","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-319","volume":"15","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis. BMC Musculoskelet. Disord. 15, 319 (2014).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1326_CR157","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/j.pain.0000000000001694","volume":"161","author":"PRW Gowler","year":"2020","unstructured":"Gowler, P. R. W. et al. Peripheral brain-derived neurotrophic factor contributes to chronic osteoarthritis joint pain. Pain 161, 61\u201373 (2020).","journal-title":"Pain"},{"key":"1326_CR158","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.41125","volume":"72","author":"SR Jafarzadeh","year":"2020","unstructured":"Jafarzadeh, S. R. et al. Mediating role of bone marrow lesions, synovitis, pain sensitization, and depressive symptoms on knee pain improvement following substantial weight loss. Arthritis Rheumatol. 72, 420\u2013427 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1326_CR159","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.soard.2021.04.019","volume":"17","author":"EAF Heuts","year":"2021","unstructured":"Heuts, E. A. F., de Jong, L. D., Hazebroek, E. J., Wagener, M. & Somford, M. P. The influence of bariatric surgery on hip and knee joint pain: a systematic review. Surg. Obes. Relat. Dis. 17, 1637\u20131653 (2021).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"1326_CR160","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.joca.2012.02.639","volume":"20","author":"H Gudbergsen","year":"2012","unstructured":"Gudbergsen, H. et al. Weight loss is effective for symptomatic relief in obese subjects with knee osteoarthritis independently of joint damage severity assessed by high-field MRI and radiography. Osteoarthr. Cartil. 20, 495\u2013502 (2012).","journal-title":"Osteoarthr. Cartil."},{"key":"1326_CR161","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40744-021-00397-7","volume":"9","author":"S Patel","year":"2022","unstructured":"Patel, S. & Kumthekar, A. Psoriatic arthritis: the influence of co-morbidities on drug choice. Rheumatol. Ther. 9, 49\u201371 (2022).","journal-title":"Rheumatol. Ther."},{"key":"1326_CR162","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10067-024-07267-x","volume":"44","author":"H Xu","year":"2025","unstructured":"Xu, H., Wang, Z., Xu, L. & Su, Y. Refractory psoriatic arthritis: emerging concepts in whole process management. Clin. Rheumatol. 44, 583\u2013590 (2025).","journal-title":"Clin. Rheumatol."},{"key":"1326_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237598","volume":"15","author":"T Blake","year":"2020","unstructured":"Blake, T., Gullick, N. J., Hutchinson, C. E. & Barber, T. M. Psoriatic disease and body composition: a systematic review and narrative synthesis. PLoS ONE 15, e0237598 (2020).","journal-title":"PLoS ONE"},{"key":"1326_CR164","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","volume":"129","author":"MD Jensen","year":"2014","unstructured":"Jensen, M. D. et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Obesity Society. Circulation 129, S102\u2013S138 (2014).","journal-title":"Circulation"},{"key":"1326_CR165","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/oby.20662","volume":"22","author":"LAR Group","year":"2014","unstructured":"Group, L. A. R. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity 22, 5\u201313 (2014).","journal-title":"Obesity"},{"key":"1326_CR166","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11695-018-3525-0","volume":"29","author":"PE O\u2019Brien","year":"2019","unstructured":"O\u2019Brien, P. E. et al. Long-Term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes. Surg. 29, 3\u201314 (2019).","journal-title":"Obes. Surg."},{"key":"1326_CR167","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M17-2786","volume":"169","author":"D Arterburn","year":"2018","unstructured":"Arterburn, D. et al. Comparative effectiveness and safety of bariatric procedures for weight loss: a PCORnet cohort study. Ann. Intern. Med. 169, 741\u2013750 (2018).","journal-title":"Ann. Intern. Med."},{"key":"1326_CR168","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ijo.2015.64","volume":"39","author":"S Upala","year":"2015","unstructured":"Upala, S. & Sanguankeo, A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int. J. Obes. 39, 1197\u20131202 (2015).","journal-title":"Int. J. Obes."},{"key":"1326_CR169","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","volume":"149","author":"P Jensen","year":"2013","unstructured":"Jensen, P. et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 149, 795\u2013801 (2013).","journal-title":"JAMA Dermatol."},{"key":"1326_CR170","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1517\/14712598.2014.900541","volume":"14","author":"N Al-Mutairi","year":"2014","unstructured":"Al-Mutairi, N. & Nour, T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert. Opin. Biol. Ther. 14, 749\u2013756 (2014).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"1326_CR171","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","volume":"88","author":"P Gisondi","year":"2008","unstructured":"Gisondi, P., Del Giglio, M., Di Francesco, V., Zamboni, M. & Girolomoni, G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am. J. Clin. Nutr. 88, 1242\u20131247 (2008).","journal-title":"Am. J. Clin. Nutr."},{"key":"1326_CR172","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/j.1468-3083.2011.04361.x","volume":"26","author":"AB Kimball","year":"2012","unstructured":"Kimball, A. B., Alavian, C., Alora-Palli, M. & Bagel, J. Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy. J. Eur. Acad. Dermatol. Venereol. 26, 1582\u20131584 (2012).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR173","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000335566","volume":"224","author":"M Del Giglio","year":"2012","unstructured":"Del Giglio, M., Gisondi, P., Tessari, G. & Girolomoni, G. Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: a randomized, investigator-blinded study. Dermatology 224, 31\u201337 (2012).","journal-title":"Dermatology"},{"key":"1326_CR174","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/bjd.12735","volume":"170","author":"L Naldi","year":"2014","unstructured":"Naldi, L. et al. Diet and physical exercise in psoriasis: a randomized controlled trial. Br. J. Dermatol. 170, 634\u2013642 (2014).","journal-title":"Br. J. Dermatol."},{"key":"1326_CR175","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/annrheumdis-2014-eular.2760","volume":"73","author":"A Abou-Raya","year":"2014","unstructured":"Abou-Raya, A., Abou-Raya, S. & Helmii, M. Effect of exercise and dietary weight loss on symptoms and systemic inflammation in obese adults with psoriatic arthritis: randomized controlled trial [abstract OP0076]. Ann. Rheum. Dis. 73, 89\u201390 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1810-5","volume":"21","author":"E Klingberg","year":"2019","unstructured":"Klingberg, E. et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res. Ther. 21, 17 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1326_CR177","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02350-5","volume":"22","author":"E Klingberg","year":"2020","unstructured":"Klingberg, E., Bjorkman, S., Eliasson, B., Larsson, I. & Bilberg, A. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res. Ther. 22, 254 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"1326_CR178","doi-asserted-by":"crossref","DOI":"10.1002\/art.42661","volume":"77","author":"L Eder","year":"2025","unstructured":"Eder, L. et al. Dietary interventions in psoriatic arthritis: a randomized controlled clinical trial [abstract]. Arthritis Rheumatol. 77, 2690 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1326_CR179","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321140","volume":"20","author":"R Ramonda","year":"2025","unstructured":"Ramonda, R. et al. Ketogenic diet improves disease activity and cardiovascular risk in psoriatic arthritis: a proof of concept study. PLoS ONE 20, e0321140 (2025).","journal-title":"PLoS ONE"},{"key":"1326_CR180","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052475","volume":"25","author":"V Lambadiari","year":"2024","unstructured":"Lambadiari, V. et al. The effect of a ketogenic diet versus Mediterranean diet on clinical and biochemical markers of inflammation in patients with obesity and psoriatic arthritis: a randomized crossover trial. Int. J. Mol. Sci. 25, 2475 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1326_CR181","doi-asserted-by":"publisher","DOI":"10.3390\/nu11030601","volume":"11","author":"M Adawi","year":"2019","unstructured":"Adawi, M. et al. The impact of intermittent fasting (Ramadan fasting) on psoriatic arthritis disease activity, enthesitis, and dactylitis: a multicentre study. Nutrients 11, 601 (2019).","journal-title":"Nutrients"},{"key":"1326_CR182","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/acr.22926","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek, A., Touma, Z., Anderson, M. & Eder, L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res. 69, 67\u201374 (2017).","journal-title":"Arthritis Care Res."},{"key":"1326_CR183","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2340\/00015555-1824","volume":"94","author":"P Jensen","year":"2014","unstructured":"Jensen, P. et al. Effect of weight loss on the cardiovascular risk profile of obese patients with psoriasis. Acta Derm. Venereol. 94, 691\u2013694 (2014).","journal-title":"Acta Derm. Venereol."},{"key":"1326_CR184","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1381\/0960892041975569","volume":"14","author":"G Higa-Sansone","year":"2004","unstructured":"Higa-Sansone, G. et al. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes. Surg. 14, 1132\u20131134 (2004).","journal-title":"Obes. Surg."},{"key":"1326_CR185","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1381\/096089206775221998","volume":"16","author":"JE de Menezes Ettinger","year":"2006","unstructured":"de Menezes Ettinger, J. E. et al. Remission of psoriasis after open gastric bypass. Obes. Surg. 16, 94\u201397 (2006).","journal-title":"Obes. Surg."},{"key":"1326_CR186","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jaad.2010.01.001","volume":"65","author":"EW Hossler","year":"2011","unstructured":"Hossler, E. W., Maroon, M. S. & Mowad, C. M. Gastric bypass surgery improves psoriasis. J. Am. Acad. Dermatol. 65, 198\u2013200 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1326_CR187","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.soard.2014.03.025","volume":"10","author":"H Romero-Talam\u00e1s","year":"2014","unstructured":"Romero-Talam\u00e1s, H. et al. Psoriasis improvement after bariatric surgery. Surg. Obes. Relat. Dis. 10, 1155\u20131159 (2014).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"1326_CR188","volume":"67","author":"M Sethi","year":"2015","unstructured":"Sethi, M., Ren-Fieldin, C., Caminer, A., Scher, J. & Reddy, S. Clinical improvements in psoriasis and psoriatic arthritis with surgical weight loss [abstract]. Arthritis Rheumatol. 67, 688 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1326_CR189","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/oby.21955","volume":"25","author":"C Maglio","year":"2017","unstructured":"Maglio, C., Peltonen, M., Rudin, A. & Carlsson, L. M. S. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish Obese Subjects Study. Obesity 25, 2068\u20132073 (2017).","journal-title":"Obesity"},{"key":"1326_CR190","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamasurg.2016.4610","volume":"152","author":"A Egeberg","year":"2017","unstructured":"Egeberg, A., S\u00f8rensen, J. A., Gislason, G. H., Knop, F. K. & Skov, L. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery. JAMA Surg. 152, 344\u2013349 (2017).","journal-title":"JAMA Surg."},{"key":"1326_CR191","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1262-3636(09)73458-5","volume":"35","author":"B Laferr\u00e8re","year":"2009","unstructured":"Laferr\u00e8re, B. Effect of gastric bypass surgery on the incretins. Diabetes Metab. 35, 513\u2013517 (2009).","journal-title":"Diabetes Metab."},{"key":"1326_CR192","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11695-011-0362-9","volume":"21","author":"L Usinger","year":"2011","unstructured":"Usinger, L. et al. Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding. Obes. Surg. 21, 625\u2013632 (2011).","journal-title":"Obes. Surg."},{"key":"1326_CR193","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","volume":"27","author":"T Ahern","year":"2013","unstructured":"Ahern, T. et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J. Eur. Acad. Dermatol. Venereol. 27, 1440\u20131443 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR194","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","volume":"38","author":"M Buysschaert","year":"2012","unstructured":"Buysschaert, M., Tennstedt, D. & Preumont, V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 38, 86\u201388 (2012).","journal-title":"Diabetes Metab."},{"key":"1326_CR195","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bjd.12380","volume":"169","author":"CT Reid","year":"2013","unstructured":"Reid, C. T., Tobin, A. M., Ahern, T., O\u2019Shea, D. & Kirby, B. Liraglutide in combination with acitretin for severe recalcitrant psoriasis. Br. J. Dermatol. 169, 230\u2013231 (2013).","journal-title":"Br. J. Dermatol."},{"key":"1326_CR196","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","volume":"150","author":"X Xu","year":"2019","unstructured":"Xu, X. et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res. Clin. Pract. 150, 167\u2013173 (2019).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1326_CR197","volume":"2021","author":"G Costanzo","year":"2021","unstructured":"Costanzo, G., Curatolo, S., Bus\u00e0, B., Belfiore, A. & Gullo, D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol. Diabetes Metab. Case Rep. 2021, 21-0007 (2021).","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"1326_CR198","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"Lin, L. et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J. Dermatol. Treat. 33, 1428\u20131434 (2022).","journal-title":"J. Dermatol. Treat."},{"key":"1326_CR199","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010046","volume":"15","author":"J Petkovi\u0107-Dabi\u0107","year":"2025","unstructured":"Petkovi\u0107-Dabi\u0107, J. et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules 15, 46 (2025).","journal-title":"Biomolecules"},{"key":"1326_CR200","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/jdv.12629","volume":"29","author":"A Faurschou","year":"2015","unstructured":"Faurschou, A. et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients \u2014 a randomized placebo-controlled trial. J. Eur. Acad. Dermatol. Venereol. 29, 555\u2013559 (2015).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR201","doi-asserted-by":"crossref","DOI":"10.1002\/art.42661","volume":"77","author":"L Eder","year":"2025","unstructured":"Eder, L. et al. Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: a retrospective analysis of two cohorts [abstract]. Arthritis Rheumatol. 77, 2687 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1326_CR202","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","volume":"51","author":"A Faurschou","year":"2014","unstructured":"Faurschou, A. et al. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 51, 147\u2013150 (2014).","journal-title":"Acta Diabetol."},{"key":"1326_CR203","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","volume":"161","author":"J Nicolau","year":"2023","unstructured":"Nicolau, J. et al. Effects of liraglutide among patients living with psoriasis and obesity. Med. Clin. 161, 293\u2013296 (2023).","journal-title":"Med. Clin."},{"key":"1326_CR204","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nri3369","volume":"13","author":"PJ Brennan","year":"2013","unstructured":"Brennan, P. J., Brigl, M. & Brenner, M. B. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13, 101\u2013117 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"1326_CR205","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1468-3083.2009.03292.x","volume":"23","author":"S Peternel","year":"2009","unstructured":"Peternel, S. & Kastelan, M. Immunopathogenesis of psoriasis: focus on natural killer T cells. J. Eur. Acad. Dermatol. Venereol. 23, 1123\u20131127 (2009).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1326_CR206","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","volume":"54","author":"AE Hogan","year":"2011","unstructured":"Hogan, A. E. et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54, 2745\u20132754 (2011).","journal-title":"Diabetologia"},{"key":"1326_CR207","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.4049\/jimmunol.1001829","volume":"185","author":"AY Wen","year":"2010","unstructured":"Wen, A. Y., Sakamoto, K. M. & Miller, L. S. The role of the transcription factor CREB in immune function. J. Immunol. 185, 6413\u20136419 (2010).","journal-title":"J. Immunol."},{"key":"1326_CR208","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","volume":"35","author":"Y Cai","year":"2011","unstructured":"Cai, Y. et al. Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation. Immunity 35, 596\u2013610 (2011).","journal-title":"Immunity"},{"key":"1326_CR209","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bjd.12886","volume":"171","author":"M Buysschaert","year":"2014","unstructured":"Buysschaert, M. et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study. Br. J. Dermatol. 171, 155\u2013161 (2014).","journal-title":"Br. J. Dermatol."},{"key":"1326_CR210","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1007\/s00018-010-0396-5","volume":"67","author":"N Marx","year":"2010","unstructured":"Marx, N. et al. Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol. Life Sci. 67, 3549\u20133555 (2010).","journal-title":"Cell Mol. Life Sci."},{"key":"1326_CR211","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal, H. et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N. Engl. J. Med. 391, 1573\u20131583 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1326_CR212","first-page":"4800","volume":"11","author":"J Mei","year":"2019","unstructured":"Mei, J., Sun, J., Wu, J. & Zheng, X. Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis. Am. J. Transl. Res. 11, 4800\u20134808 (2019).","journal-title":"Am. J. Transl. Res."},{"key":"1326_CR213","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05323-7","volume":"12","author":"C Meurot","year":"2022","unstructured":"Meurot, C. et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci. Rep. 12, 1567 (2022).","journal-title":"Sci. Rep."},{"key":"1326_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2025.100567","volume":"7","author":"J Cheng","year":"2025","unstructured":"Cheng, J., Solomon, T., Estee, M., Cicuttini, F. M. & Lim, Y. Z. Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: a systematic review of pre-clinical and human studies. Osteoarthr. Cartil. Open 7, 100567 (2025).","journal-title":"Osteoarthr. Cartil. Open"},{"key":"1326_CR215","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00415-020-09813-4","volume":"267","author":"K Malhotra","year":"2020","unstructured":"Malhotra, K. et al. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis. J. Neurol. 267, 2117\u20132122 (2020).","journal-title":"J. Neurol."},{"key":"1326_CR216","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.diabres.2019.02.014","volume":"150","author":"B Sinha","year":"2019","unstructured":"Sinha, B. & Ghosal, S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res. Clin. Pract. 150, 8\u201316 (2019).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1326_CR217","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf346","author":"H Olbrich","year":"2025","unstructured":"Olbrich, H. et al. GLP-1RA and reduced mortality, cardiovascular and psychiatric risks in psoriasis: a large-scale cohort study. Br. J. Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljaf346 (2025).","journal-title":"Br. J. Dermatol."},{"key":"1326_CR218","volume":"77","author":"N Tsibadze","year":"2025","unstructured":"Tsibadze, N., Tskhakaia, I. & Tan, I. Mortality and major adverse cardiac events (MACE) with GLP-1 receptor agonists in psoriatic arthritis [abstract]. Arthritis Rheumatol. 77, 0849 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1326_CR219","volume":"17","author":"JP Patel","year":"2025","unstructured":"Patel, J. P. et al. Comparative effectiveness of semaglutide, liraglutide, orlistat, and phentermine for weight loss in obese individuals: a systematic review. Cureus 17, e80321 (2025).","journal-title":"Cureus"},{"key":"1326_CR220","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1046\/j.1365-2133.2002.04806.x","volume":"147","author":"R Ryback","year":"2002","unstructured":"Ryback, R. Topiramate in the treatment of psoriasis: a pilot study. Br. J. Dermatol. 147, 130\u2013133 (2002).","journal-title":"Br. J. Dermatol."},{"key":"1326_CR221","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/j.jemermed.2016.11.034","volume":"52","author":"PA Singh","year":"2017","unstructured":"Singh, P. A., Cassel, K. P., Moscati, R. M. & Eckersley, D. Acute generalized erythrodermic pustular psoriasis associated with bupropion\/naltrexone (Contrave\u00ae). J. Emerg. Med. 52, e111\u2013e113 (2017).","journal-title":"J. Emerg. Med."},{"key":"1326_CR222","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jdcr.2023.07.009","volume":"39","author":"J Eakes","year":"2023","unstructured":"Eakes, J., Moore, S., Hennessy, K. & Lin, A. Naltrexone-induced acute generalized exanthematous pustulosis. JAAD Case Rep. 39, 115\u2013117 (2023).","journal-title":"JAAD Case Rep."},{"key":"1326_CR223","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1326_CR224","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ehjcvp\/pvaa133","volume":"8","author":"M Ardissino","year":"2022","unstructured":"Ardissino, M. et al. Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study. Eur. Heart J. Cardiovasc. Pharmacother. 8, 179\u2013186 (2022).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"1326_CR225","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen, S. E. et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 315, 990\u20131004 (2016).","journal-title":"JAMA"},{"key":"1326_CR226","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13224","volume":"22","author":"AC Sposito","year":"2021","unstructured":"Sposito, A. C. et al. Cardiovascular safety of naltrexone and bupropion therapy: systematic review and meta-analyses. Obes. Rev. 22, e13224 (2021).","journal-title":"Obes. Rev."},{"key":"1326_CR227","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1210\/jc.2018-01010","volume":"104","author":"ME Ritchey","year":"2019","unstructured":"Ritchey, M. E. et al. Cardiovascular safety during and after use of phentermine and topiramate. J. Clin. Endocrinol. Metab. 104, 513\u2013522 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1326_CR228","volume":"16","author":"KN Islam","year":"2024","unstructured":"Islam, K. N. et al. Obesity medications and their impact on cardiovascular health: a narrative review. Cureus 16, e71875 (2024).","journal-title":"Cureus"},{"key":"1326_CR229","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker, D. J. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care 47, 1873\u20131888 (2024).","journal-title":"Diabetes Care"},{"key":"1326_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1446468","volume":"11","author":"A Skrobucha","year":"2024","unstructured":"Skrobucha, A., Pindlowski, P., Krajewska, N., Grabowski, M. & Jonik, S. Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review. Front. Cardiovasc. Med. 11, 1446468 (2024).","journal-title":"Front. Cardiovasc. Med."},{"key":"1326_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01821-3","volume":"25","author":"W Halloum","year":"2024","unstructured":"Halloum, W., Dughem, Y. A., Beier, D. & Pellesi, L. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. J. Headache Pain. 25, 112 (2024).","journal-title":"J. Headache Pain."},{"key":"1326_CR232","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ard.2025.06.619","volume":"84","author":"H Marzo-Ortega","year":"2025","unstructured":"Marzo-Ortega, H. et al. EULAR points to consider for the definitions of difficult-to-manage and treatment-refractory psoriatic arthritis [abstract POS1269]. Ann. Rheum. Dis. 84, 1319\u20131320 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR233","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102782","volume":"75","author":"N Alfaris","year":"2024","unstructured":"Alfaris, N. et al. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. eClinicalMedicine 75, 102782 (2024).","journal-title":"eClinicalMedicine"},{"key":"1326_CR234","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1093\/rheumatology\/keab304","volume":"60","author":"AA Sherbini","year":"2021","unstructured":"Sherbini, A. A., Sharma, S. D., Gwinnutt, J. M., Hyrich, K. L. & Verstappen, S. M. M. Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. Rheumatology 60, 4001\u20134017 (2021).","journal-title":"Rheumatology"},{"key":"1326_CR235","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1365-2710.2000.00296.x","volume":"25","author":"PJ Hewitson","year":"2000","unstructured":"Hewitson, P. J., Debroe, S., McBride, A. & Milne, R. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. J. Clin. Pharm. Ther. 25, 295\u2013302 (2000).","journal-title":"J. Clin. Pharm. Ther."},{"key":"1326_CR236","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh, A. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020\u20131026 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1326_CR237","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jaad.2024.12.016","volume":"92","author":"J Burshtein","year":"2025","unstructured":"Burshtein, J. et al. The association between obesity and efficacy of psoriasis therapies: an expert consensus panel. J. Am. Acad. Dermatol. 92, 807\u2013815 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1326_CR238","volume":"28","author":"S Sheth","year":"2025","unstructured":"Sheth, S., Inestroza, K., Merola, J. F., Weber, B. & Garshick, M. Practical recommendations on cardiovascular risk evaluation in patients with psoriasis and psoriatic arthritis for dermatologists, rheumatologists, and primary care physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network. J. Psoriasis Psoriatic Arthritis 28, 24755303251337020 (2025).","journal-title":"J. Psoriasis Psoriatic Arthritis"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01326-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01326-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01326-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T01:02:30Z","timestamp":1772067750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01326-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":238,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1326"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01326-6","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"31 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.H.H. has served as a consultant to Johnson & Johnson and Novartis. A.O. has received grant support from AbbVie, Johnson & Johnson, Novartis and Pfizer, and to Forward database from Amgen and Bristol Myers Squibb; and has served as a consultant fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, Lilly, Gilead, Happify, Janssen, Novartis, Pfizer and UCB. J.F.M. has received personal fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Janssen, Lilly, Moonlake, UCB and Novartis; and has received grants from Pfizer and Sun Pharma. J.U.S. has served as a consultant for AbbVie, Johnson & Johnson, Kaleido, Novartis, Pfizer, Sanofi and UCB; and has received funding for investigator-initiated studies from Johnson & Johnson, Novartis, and Pfizer. L.E. has received grants from AbbVie, Pfizer, Johnson & Johnson, UCB, Novartis and Lilly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}